-
公开(公告)号:ECSP941065A
公开(公告)日:1994-12-15
申请号:ECSP941065
申请日:1994-04-12
Applicant: GLAXO INC
Inventor: SUGG ELIZABETH E , AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , HENKE BRAD RICHARD , BRACKEEN MARCUS , JEFFS PETER WALTER , SUH EDWARD MARTIN , HIRST GAVIN CHARLES , WILLSON TIMOTHY MARK , MOMTAHEN TANYA
IPC: A61K20060101 , A61K38/00 , C07D20060101
Abstract: Novedosos como el proceso para su preparación, con las composiciones farmacéuticas que los contienen y con su uso en medicina, más particularmente, se relaciona con compuestos que exhiben actividad egonista para los receptores de CCK-A permitiéndoles por tanto modular las hormonas gastrina y colecistocinina en mamíferos.
-
公开(公告)号:ZA9503056B
公开(公告)日:1996-01-30
申请号:ZA9503056
申请日:1995-04-13
Applicant: GLAXO INC
Inventor: AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , HENKE BRAD RICHARD , BRACKEEN MARCUS , JEFFS PETER WALTER , SUH EDWARD MARTIN , HIRST GAVIN CHARLES , SUGG ELIZABETH ELLEN , WILLSON TIMOTHY MARK , MOMTAHEN TANYA
IPC: A61K20060101 , C07D20060101 , C07D , A61K
-
公开(公告)号:ZA953111B
公开(公告)日:1996-01-23
申请号:ZA953111
申请日:1995-04-18
Applicant: GLAXO INC
Inventor: AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , SUGG ELIZABETH ELLEN , SHERRILL RONALD GEORGE , WILLSON TIMOTHY MARK , SZEWCZYK JERZY RYSZARD
IPC: A61K20060101 , C07D20060101 , C07D , A61K
-
公开(公告)号:AU2446295A
公开(公告)日:1995-11-10
申请号:AU2446295
申请日:1995-04-13
Applicant: GLAXO INC
Inventor: AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , SUGG ELIZABETH ELLEN , SHERRILL RONALD GEORGE , WILLSON TIMOTHY MARK , SZEWCZYK JERZY RYSZARD
IPC: C07D243/14 , A61K31/55 , A61K31/551 , A61K31/5513 , A61P1/00 , A61P1/16 , A61P3/04 , A61P25/00 , A61P43/00 , C07D243/24 , C07D401/04 , C07D403/06 , C07D403/12 , C07D487/04
Abstract: PCT No. PCT/EP95/01335 Sec. 371 Date Oct. 11, 1996 Sec. 102(e) Date Oct. 11, 1996 PCT Filed Apr. 13, 1995 PCT Pub. No. WO95/28399 PCT Pub. Date Oct. 26, 1995A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), (I) where R1 is C1-C6alkyl, C3-6cycloalkyl, phenyl, or substituted phenyl; R2 is C3-6alkyl, C3-6cycloalkyl, C3-6alkenyl, benzyl, phenylC1-3alkyl or substituted phenyl; or NR1R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C1-6alkyl, C1-6alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0,1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R3, R4, R5 and R8 are selected from a variety of substituents; X is nitrogen, nitroso or R8; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).
-
公开(公告)号:ZA953056B
公开(公告)日:1996-01-30
申请号:ZA953056
申请日:1995-04-13
Applicant: GLAXO INC
Inventor: AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , HENKE BRAD RICHARD , BRACKEEN MARCUS , JEFFS PETER WALTER , SUH EDWARD MARTIN , HIRST GAVIN CHARLES , SUGG ELIZABETH ELLEN , WILLSON TIMOTHY MARK , MOMTAHEN TANYA
IPC: A61K20060101 , C07D20060101 , C07D , A61K
-
公开(公告)号:ZA9503111B
公开(公告)日:1996-01-23
申请号:ZA9503111
申请日:1995-04-18
Applicant: GLAXO INC
Inventor: AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , SUGG ELIZABETH ELLEN , SHERRILL RONALD GEORGE , WILLSON TIMOTHY MARK , SZEWCZYK JERZY RYSZARD
IPC: A61K20060101 , C07D20060101 , C07D , A61K
-
公开(公告)号:PE27497A1
公开(公告)日:1997-08-07
申请号:PE26622595
申请日:1995-04-11
Applicant: GLAXO INC
Inventor: HENKE BRAD RICHARD , SUGG ELIZABETH ELLEN , AQUINO CRISTOPHER JOSEPH , DEZUBE MILANA , WILLSON TIMOTHY MARK , BRACKEEN MARCUS , JEFFS PETER WALTER , SUH EDWARD MARTIN , MOMTAHEN TANYA , HIRST GAVIN CHARLES
IPC: C07D243/12 , A61K31/55 , A61P1/00 , A61P1/16 , A61P3/04 , C07D401/04 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D413/06 , C07D471/04 , C07D498/04
Abstract: SE REFIERE A COMPUESTOS DE FORMULA GENERAL I, DONDE: R1 ES PREFERENTEMENTE ISOPROPILO; R2 ES PREFERENTEMENTE FENILO O 4-METOXIFENILO; p, q, r Y t son 0 o 1, SIEMPRE QUE SI r ES 0, ENTONCES t ES 0; R3, R5 Y R6 SON H O ALQUILO(C1-C6); R4 ES ALQUILENO(C1-C6) O ALQUENILENO(C2-C6); R7 ES FENILO OPCIONALMENTE SUSTITUIDO POR AMINO O HALOGENO, ENTRE OTROS O ES BICICLOHETEROARILO, ENTRE OTROS, Y SI n, p Y q SON 1 Y r ES 0, ENTONCES R7 NO ES INDOLILO; o NR6R7 FORMAN UN ANILLO DE 5, 6 o 7 MIEMBROS (DE 1, 2, 3 o 4 ATOMOS DE N, S, O: SIEMPRE QUE O o S NO ESTEN UNIDOS O ENTRELAZADOS ENTRE SI); R10 ES H O BENCILO, ENTRE OTROS; R11 ES H O CICLOALQUILO(C3-C6), ENTRE OTROS; R8 ES H, METILO O METOXI, ENTRE OTROS; m ES 0, 1, 2, 3 o 4; R9 ES FENILO O PIRIDILO, ENTRE OTROS; Y Y Z SON H, HALOGENO O SAL DE ADICION. TAMBIEN SE REFIERE A LOS PROCEDIMIENTOS DE PREPARACION, QUE COMPRENDEN: HACER REACCIONAR UN COMPUESTO II CON R7COOH, Y LO OBTENIDO HACERLO REACCIONAR CON NHR6R7; HACER REACCIONAR EL COMPUESTO II CON NHR6R7; HACER REACCIONAR UN COMPUESTO III CON R7(R4)pCH(R3)HALOGENO; HACER REACCIONAR UN COMPUESTO IV CON (CLCO)(CLOC)C(R8)(CH(R3)((R4)p(CO)rR7)). ESTOS COMPUESTOS ACTUAN COMO AGONISTAS DE LOS RECEPTORES CCK-A, QUE REGULA LA HORMONA GASTRINA Y COLECISTOCININA. SIENDO USADOS PARA SACIAR EL APETITO O EN EL TRATAMIENTO DE LA DIABETES, ENTRE OTROS
-
公开(公告)号:AU2306295A
公开(公告)日:1995-11-10
申请号:AU2306295
申请日:1995-04-13
Applicant: GLAXO INC
Inventor: AQUINO CHRISTOPHER JOSEPH , DEZUBE MILANA , HENKE BRAD RICHARD , BRACKEEN MARCUS , JEFFS PETER WALTER , SUH EDWARD MARTIN , HIRST GAVIN CHARLES , SUGG ELIZABETH ELLEN , WILLSON TIMOTHY MARK , MOMTAHEN TANYA
IPC: A61K31/55 , A61P1/00 , A61P1/16 , A61P3/04 , C07D243/12 , C07D401/04 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D409/14 , C07D413/06 , C07D471/04 , C07D498/04
Abstract: PCT No. PCT/EP95/01336 Sec. 371 Date Nov. 14, 1996 Sec. 102(e) Date Nov. 14, 1996 PCT Filed Apr. 13, 1995 PCT Pub. No. WO95/28391 PCT Pub. Date Oct. 26, 1995 (I) Benzo[b][1,4]diazepine compounds of formula (I), where R1 is selected from C1C6alkyl, C3-C6cycloalkyl, phenyl, or substituted phenyl; R2 is selected from C3-C6alkyl, C3C6cycloalkyl, C3-C6alkenyl, benzyl, phenylC1-C3alkyl of substituted phenyl; or NR1R2 together form 1,2,3,4-tetrahydroquinoline or benzazepine, mono-, di-, or trisubstituted independently with C1-6alkyl C1-6alkoxy or halogen substituents; p is an integer 0 or 1; q is an integer 0 or 1; r is an integer 0 or 1; t is an integer 0 or 1, provided that when r is 0 then t is 0; R3, R5, and R6 are independently hydrogen or C1-6alkyl; R4 is C1-6alkyl or C1-6alkenyl; R7 is selected from the group consisting of hydrogen, C1-6alkyl, C1-6cycloalkyl, C1-6alkenyl, phenyl, substituted phenyl, napthyl, heteroaryl, substituted heteroaryl, bicycloheteroaryl or substituted bicycloheteroaryl; or NR6R7 together form a saturated 5,6, or 7 membered ring optionally interrupted by 1,2,3 or 4 N, S or O heteroatoms, with the proviso that any two O or S atoms are not bonded to each other, m is an integer selected from the group of 0, 1, 2, 3 or 4; R8 and R9 are selected from a variety of substituents; Z is hydrogen or halogen; novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).
-
-
-
-
-
-
-